Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nothing on Schwab yet. looking and hoping!!
Alapis from your post just over 1 month ago "Soo many pieces of the puzzle come together..Gerald is executing his business plan step by step and this will ultimately lead to huge sharholder value...i have no doubt that this stock will trade way above 0.10 in the near future...in fact this can happen any day with news from MNAF JV for the second orphan drug indication or a partnership for Lympro...the stock price is a gift at the moment
Big change in your opinion.
From Dr. Lowe " orphan indications such as Retinitis Pigmentosa present a tremendous opportunity to speed the time to market for MANF, thereby increasing its net present value at the same time as facilitating success in PD and other indications that have more complicated regulatory pathways."
Buying more today!!
Thanks for being concerned about us shareholders!
About Bascom Palmer "Founded in 1962, Bascom Palmer is the largest ophthalmic care, research and educational facility in the southeastern United States. Its staff treats more than 250,000 patients and performs more than 13,000 surgeries annually. At the forefront of innovation in ophthalmology for more than five decades, the institute’s physicians and scientists are internationally recognized for their expertise in every eye disorder, including glaucoma, macular degeneration, diabetic retinopathy, cataracts, dry eye, eye cancers and eye diseases in children.
Bascom Palmer has nearly 80 faculty and researchers working on revolutionary ways to treat eye disorders and disease, including research that could reverse vision loss in demyelinating diseases, such as multiple sclerosis. Bascom Palmer also continues to be a leader in age-related macular degeneration research and education."
I would say this helps us!!
American Bulls buy signal today "BULLISH HARAMI CROSS ". Just sayin.
100,000+ buys coming in!!!
You can issue all the stock in the world but if nobody is buying it's not worth the paper it's printed on. I can't figure who bought all the shares in the last 6 months!!
10Q out. Didn't see anything about the dividend. Lots of stock issued to the family. :( Not much revenue. Not a very good report. imo
http://www.sec.gov/Archives/edgar/data/1335239/000101968713004465/0001019687-13-004465-index.htm
Buys coming in. Could this be the start of another rally?
Atta boy Gerald!!
Losses offset by hiring the dream team. 5 million loss vs potential 500 million lymPro annually.
Spend 5 million now vs 500 million profit from LimPro annually no brainer here.
From Presidents letter to shareholder's:
It is estimated that the cost of caring for patients with dementia will exceed $200B in 2013; we believe the potential for LymPro exceeds $500M annually;
• The market for Parkinson's diseases drugs exceeded $3B worldwide in 2008; we believe the market potential for MANF in Parkinson's exceeds $1B annually;
• The market for the orphan indications currently being evaluated under our CEAR grant exceeds $1B; we believe the market potential for MANF in these orphan indications exceeds $1B annually;
• The markets for diabetes, ischemic heart disease and traumatic brain injury exceeds $100B annually; we believe the market potential for MANF in other indications exceeds $3B annually;
Dr.John W. Commissiong "PhenoGuard" Atta Boy Dr. John!!
From helperwatson at another board Quote" Dr. Lowe and I met a long time ago at Leeds in West Yorkshire. He has been quite impressive in the past with Bayer and really built a reputation in the industry with CNS related diseases and study. He has worked around Lympro in the past and with MANF. He was brought on with intent, Gerald is surrounding himself with good people. No one brings a board on like this without serious intent to change the world of medicine as we know it. You want people on the board that certify/validate what you do with their name, and also people that leverage pharma and the feds whether it be EMEA or the FDA, Lowe is perfect on all accounts to help with retina launch and with Lympro marketing. The timing is key on this one for his arrival and I was actually surprised they got him on board. He's quite prolific in the field as a five star general of CNS disorders. One thing you will see about Lowe's past, he is aggressive and doesn't sign on until something is ready to move, read about his background and look at the disorders he has worked with and then look at the products he has helped move, impressive"
Since 2008 AMBS has been working to get to a point of marketing a product. In the last year they have been assembling a team to do just that. They are on the verge of something big and I think Gerald is doing a good job of bringing in the talent. These guys don't sign on something unless they know it has huge potential. imo
With all this high priced talent coming on board, I would expect something to happen in the 1st or 2nd quarter of 2014.
Dr. Lowe has more than 25 years of experience in pharmaceutical drug discovery and product development and an established track record of generating diverse clinical candidates.
Dr. David Lowe, another member of the team added. So much talent added to AMBS in the last year.
Dominion Capitol. Does anyone here know who they (or he) really is? Check it out! Toxic I don't think so. imo
and Dominion Capitol is helping with the accounts payable. Not to mention Dominion's investment has grown over 3 million dollars in the run up from .03 per share in the last couple months. Does anyone really think Dominion would let them go bankrupt? Ha Ha good joke. imo
About QB3
QB3 is a cooperative effort among private industry and more than 220 scientists at UC San Francisco, UC Berkeley and UC Santa Cruz. One of four technology institutes created in 2000 by former California Governor Gray Davis, QB3 has a joint mission of supporting science, driving the California economy and transforming scientific research into public good.
Fundamental to the latter two missions are QB3's efforts to commercialize University of California science by creating mutually beneficial partnerships with industry and supporting innovative entrepreneurs. The effort has led to 54 bioscience startup companies currently in QB3's incubator network. QB3 also operates Mission Bay Capital, an $11.3M seed-stage venture capital fund designed to support UC startups. For more information on QB3, visit www.qb3.org.
100000 for sale .0095 at Schwab
At least we didn't loose anything more today......
Those who said Dr. Rubinfeld had no skin in the game a while back have just been provin wrong!!
Man that was like Ali and Frazier for the last 15 minutes!!! All we needed was Howard Cosell
Big fight going on!!!
Added some 55's. with whoever else is doing this!!
Lots of buys at 55!!
Ha Ha Ha KMAG doesn't get no respect!!
Considering the selling volume is 5 to 1 we are holding up pretty well today. Seeing selling below the bid tells me the MM's want it lower so they can load up later. imo
Seems to me if the CEO cared about shareholders he would be reassuring and updating us that KMAG was doing ok. Instead he is out sporting around in the atv scratching around in the dirt. Last update almost 6mo ago. shame shame shame... Not so good of a CEO imo.
Looking for my dividend. Hope it shows up within 5 to 7 days. Other stocks I have had it generally takes around that length of time.
BD would not let AMBS use there name in anyway if they were not on friendly terms and in the "thick" of things. I see good thing developing with BD. imo
Becton Dickinson the giant in the room hooked up with little old AMBS. WOW Happy Happy Happy!!!
Becton Dickinson's Custom Technology Team and AMBS working together. BD wouldn't waste there time if the results weren't good. They would just move on. Going to be great!! imo
AMBS "improving it's marketability" with Becton Dickinson's Custom Technology Team.
Tweeted " On Sept. 18th 2013, $AMBS CEO met with Becton Dickinson's Custom Technology Team (CTT) accompanied by Corporate Advisor Dr. Adam Simon"
"Many important business & scientific topics were discussed, including the current status of the assay, & ways to improve its marketability"